Is Seelos Therapeutics a good investment?

Is Seelos Therapeutics a good investment?

Seelos Therapeutics has received a consensus rating of Buy.

Similarly, Is SEEL undervalued?

The last rating was given by B. Riley Securities on Mar 14, 2022. The price target was changed from 0.85 to 7.61.

Predicted Opening Price for Seelos Therapeutics Inc. of Tuesday, April 12, 2022.

Fair opening price April 12, 2022 Current price
$0.81 $0.80 (Undervalued)

What does Seelos therapeutics do? Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders.

Thereof, What happened to Apricus Biosciences?

Apricus Biosciences Inc. completed the company’s merger with private biotechnology company Seelos Therapeutics Inc.

Where is Seelos Therapeutics located?

The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.

Join community and don’t forget to share this post !

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.